Literature DB >> 10929036

JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.

J De Vos1, M Jourdan, K Tarte, C Jasmin, B Klein.   

Abstract

Cytokines of the interleukin 6 (IL-6) family, which activates the signal transducer gp130, are major survival and growth factors for human multiple myeloma (MM) cells. The signal transduction of gp130 involves the Janus tyrosine kinases (JAK) JAK1, JAK2 and Tyk2 and then the downstream effectors comprising the signal transducer and activator of transcription 3 (STAT3) and mitogen-activated protein kinase (MAPK) pathways. We evaluated the effects of the JAK2 inhibitor tyrphostin AG490 on MM cells. We found that AG490 suppressed cell proliferation and induced apoptosis in IL-6-dependent MM cell lines. JAK2 kinase activity, ERK2 and STAT3 phosphorylation were inhibited. These results suggest that the chemical blocking of the gp130 signalling pathway at the JAK level could be a relevant therapeutic approach to MM.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929036     DOI: 10.1046/j.1365-2141.2000.02127.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  41 in total

Review 1.  Modulation of hepcidin to treat iron deregulation: potential clinical applications.

Authors:  Nicole L Blanchette; David H Manz; Frank M Torti; Suzy V Torti
Journal:  Expert Rev Hematol       Date:  2015-12-15       Impact factor: 2.929

2.  Bcl-xl expression in multiple myeloma.

Authors:  S D P W M Peeters; S Hovenga; S Rosati; E Vellenga
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.

Authors:  Seungchan Yang; Kyungho Park; James Turkson; Carlos L Arteaga
Journal:  Exp Cell Res       Date:  2007-09-08       Impact factor: 3.905

4.  Change of mouse CD5(+) B1 cells to a macrophage-like morphology induced by gamma interferon and inhibited by interleukin-4.

Authors:  Naoki Koide; Tsuyoshi Sugiyama; Isamu Mori; Mya Mya Mu; Teruaki Hamano; Tomoaki Yoshida; Takashi Yokochi
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

5.  BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate.

Authors:  Przemyslaw Juszczynski; Jeffery L Kutok; Cheng Li; Joydeep Mitra; Ricardo C T Aguiar; Margaret A Shipp
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

6.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

7.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Authors:  Michel Jourdan; Jean-Luc Veyrune; John De Vos; Nicole Redal; Guilhem Couderc; Bernard Klein
Journal:  Oncogene       Date:  2003-05-15       Impact factor: 9.867

8.  P300-dependent STAT3 acetylation is necessary for angiotensin II-induced pro-fibrotic responses in renal tubular epithelial cells.

Authors:  Jun Ni; Yang Shen; Zhen Wang; De-cui Shao; Jia Liu; Ya-li Kong; Lan-jun Fu; Li Zhou; Hong Xue; Yu Huang; Wei Zhang; Chen Yu; Li-min Lu
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

9.  An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

Authors:  Karène Mahtouk; Michel Jourdan; John De Vos; Catherine Hertogh; Geneviève Fiol; Eric Jourdan; Jean-François Rossi; Bernard Klein
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

10.  Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells.

Authors:  H Siavash; N G Nikitakis; J J Sauk
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.